Salvage Chemotherapy in Recurrent Platinum-Resistant or Refractory Epithelial Ovarian Cancer with Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox<sup>®</sup>) - Concepedia

Concepedia

Publication | Open Access

Salvage Chemotherapy in Recurrent Platinum-Resistant or Refractory Epithelial Ovarian Cancer with Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox<sup>®</sup>)

DOI Full Paper Access

19

Citations

32

References

2013

Year

Nipon Khemapech, Shina Oranratanaphan, Wichai Termrungruanglert, Ruangsak Lertkhachonsuk, A. Vasurattana

Asian Pacific Journal of Cancer Prevention

Abstract

DPLD, the second-generation PLD drug combined with carboplatin every 4 weeks, is effective and has low toxicity for treatment of patients with recurrent platinum-resistant or refractory epithelial ovarian cancer.

References

	Year	Citations
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer William P. McGuire, William J. Hoskins, Mark F. Brady, New England Journal of Medicine	1996	2.9K
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Demetrios Papahadjopoulos, Theresa M. Allen, Alberto Gabizón, Proceedings of the National Academy of Sciences Cell-based Drug DeliveryNanomedicineLipid PreparationDrug TargetingEngineering	1991	1.6K
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Alberto Gabizón, Raphael Catane, Beatrice Uziely, PubMed EngineeringCirculation TimePathologyDoxorubicin MetabolitesExtracellular Microvesicles	1994	1.4K
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan Alan N. Gordon, John Fleagle, David Guthrie, Journal of Clinical Oncology	2001	1.2K
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Alberto Gabizón, Demetrios Papahadjopoulos Proceedings of the National Academy of Sciences Liposome ConcentrationImmunologyExtracellular MicrovesiclesRapid ClearanceProlonged Circulation Time	1988	1.1K
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Franco M. Muggia, John D. Hainsworth, Susan Jeffers, Journal of Clinical Oncology	1997	656
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Alan N. Gordon, Margaret Tonda, Steven Sun, Gynecologic Oncology Pegylated Liposomal DoxorubicinMedicineCancer ManagementGynecologyLong-term Survival Advantage	2004	430
Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer Alan N. Gordon, C.O. Granai, Peter G. Rose, Journal of Clinical Oncology	2000	343
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. M. A. Bookman, Henric Malmström, Giorgio Bolis, Journal of Clinical Oncology	1998	334
Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. S.K. Huang, K D Lee, Keelung Hong, PubMed Vivo DistributionPathologyExtracellular MicrovesiclesBiomedical EngineeringLipid Movement	1992	299

Page 1